New combo therapy aims to beat tough blood cancer
NCT ID NCT06712121
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining two drugs, venetoclax and decitabine, can help adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to treatment. The study will enroll 28 participants and measure how many achieve complete remission. The goal is to find a new option for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax and decitabine
What this could lead to
If successful, this combination could offer a new treatment option for patients whose T-cell leukemia/lymphoma has not responded to standard therapy.
What could go wrong
This is a small, early-phase trial with only 28 participants, so results may not apply broadly. The drugs can cause serious side effects like low blood counts and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Seoul National University Bundang Hospital
NOT_YET_RECRUITINGSeongnam-si, 13620, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, 03080, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••